John L. Marshall, MD

Articles

Dr Marshall on the Role of Fruquintinib in the Treatment Paradigm for mCRC

August 20th 2025

John L. Marshall, MD, discusses the use of fruquintinib in the treatment of patients with metastatic colorectal cancer.

Experts Weigh In on the Treatment of mCRC

July 30th 2025

Panelists discuss how important clinical pearls include early genomic profiling, emphasizing lifestyle modifications like exercise programs that can reduce recurrence by 7%, and using olanzapine as the most effective antiemetic for delayed chemotherapy-related nausea.

Expert Perspectives on Balancing Therapy Decisions and Quality of Life in mCRC

July 30th 2025

Panelists discuss how immunotherapy generally provides better quality of life compared to traditional chemotherapy, particularly noting that microsatellite instability-high patients on immune checkpoint inhibitors report significantly better experiences than those on FOLFOX regimens.

Quality of Life Assessment Tools In mCRC

July 23rd 2025

Panelists discuss how they assess quality of life in clinical practice by asking simple questions like “What do you do for fun?” and “How was your week?” rather than relying solely on formal quality of life questionnaires.

Defining Clinically Meaningful Outcomes and Looking Ahead at Future Treatment Options for mCRC

July 23rd 2025

Panelists discuss how they’re excited about future combination therapies, particularly TAS-102 with fruquintinib and novel immunotherapy approaches targeting patients with liver metastases who are typically checkpoint inhibitor refractory.

The Role of Chemotherapy in Third-Line mCRC Treatment

July 16th 2025

Panelists discuss how they approach rechallenge with chemotherapy, considering it primarily in patients who never truly progressed on oxaliplatin-based therapy or those who might benefit from EGFR antibody reintroduction after a drug holiday.

Fruquintinib in Practice: Nuances of Treatment Management and Future Combination Approaches

July 16th 2025

Panelists discuss how they manage fruquintinib dosing by starting at lower doses (3 to 4 mg) in patients with poor performance status or frailty, then titrating up as tolerated rather than starting at the full 5-mg dose.

SUNLIGHT Regimen in Third-Line mCRC: Insights on Treatment Management and Practical Nuances

July 9th 2025

Panelists discuss how they modify dosing schedules for TAS-102 (trifluridine/tipiracil), with some preferring every-other-week dosing instead of the standard 2-weeks-on schedule to reduce neutropenia and improve tolerability.

Role of Regorafenib in Third-Line mCRC: Expert Insights on Treatment Strategies and Management Nuances

July 9th 2025

Panelists discuss how clinical trials remain the preferred option in third-line treatment, while acknowledging that regorafenib may benefit from dose reduction strategies and potential combination with immunotherapy in select patients.

A Review of the Treatment Options in Third-Line mCRC and Therapy Sequencing Strategies

June 30th 2025

Panelists discuss how 3 drugs (regorafenib, TAS-102, and fruquintinib) offer modest but meaningful survival benefits in treatment-refractory colorectal cancer, with TAS-102 plus bevacizumab being the preferred combination when tolerated.

The Role of ctDNA in the Management of mCRC

June 30th 2025

Panelists discuss how circulating tumor DNA testing serves as the best prognostic technology available, particularly useful for identifying high-risk stage II patients who would benefit from adjuvant therapy, though surveillance strategies for positive results remain unclear.

CheckMate 8HW Expanded Analysis at ASCO 2025: Implications for Treatment Decisions in MSI-H mCRC

June 23rd 2025

Panelists discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the “hit hard, hit early” approach.

Expert Insights: BREAKWATER Survival Data Update From ASCO 2025

June 23rd 2025

Panelists discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated colorectal cancer, turning a historically poor prognostic marker into a targetable opportunity.

DPD Testing and Medication Dosage Adjustments in mCRC Patients

June 16th 2025

Panelists discuss how dihydropyrimidine dehydrogenase testing remains controversial with institutions debating whether to implement universal pharmacogenomic testing given the challenges of standardization, genotype-phenotype correlation, and low incidence of severe deficiency.

The Importance of Biomarker Testing in mCRC

June 16th 2025

John L. Marshall, MD; Marwan G. Fakih, MD; Arvind N. Dasari, MD, MS; and Katrina S. Pedersen, MD, discuss how precision medicine has transformed metastatic colorectal cancer treatment through comprehensive molecular testing, targeted therapies like BRAF/EGFR inhibition and immunotherapy combinations for microsatellite instability-high tumors, and personalized approaches to treatment sequencing and dosing modifications that balance efficacy with quality of life considerations.

Dr Marshall on Updates in CRC Following the 2024 ASCO Annual Meeting

June 17th 2024

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

Trajectory of CRC Treatment Landscape

May 6th 2024

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

May 6th 2024

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

CIRCULATE-NORTH AMERICA and Barriers to Enrollment

April 29th 2024

Stacey Cohen, MD, discusses the rationale and study design of the phase 2/3 CIRCULATE-NORTH AMERICA study evaluating adjuvant chemotherapy selection based on MRD, and the panel discusses barriers to enrollment.

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

April 29th 2024

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.